Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Capital One 1st Annual Biotech/Biopharma Disruptors Event (May 2024)
8 slides from Ani Pharmaceuticals's conference presentation, May 14, 2024
Slide 1: Capital One 1st Annual Biotech/Biopharma Disruptors Event
© 2024 ANI Pharmaceuticals, Inc. 1 Capital One 1st Annual Biotech/Biopharma Disruptors Event May 14, 2024
Slide 2: Disclaimer
© 2024 ANI Pharmaceuticals, Inc. 2 Disclaimer To the extent any statements made in this presentation deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not lim
Slide 3: ANI Pharmaceuticals: Rare Disease Business expected to be the largest driver of growth
© 2024 ANI Pharmaceuticals, Inc. 3 ANI Pharmaceuticals: Rare Disease Business expected to be the largest driver of growth Rare Disease business with lead asset Purified Cortrophin® Gel and expansion through M&A and in- licensing *Based on midpoint of 2024 Guidance shared on Q1 2024 earnings call (Ma
Slide 4: Why Purified Cortrophin Gel?
© 2024 ANI Pharmaceuticals, Inc. 4 Why Purified Cortrophin® Gel? Cortrophin Gel is purified corticotropin (ACTH), a treatment option for patients struggling with certain chronic autoimmune disorder Re-introduced a much-needed patient and physician choice into the U.S. ACTH market (only one ACTH prod
Slide 5: Investing in the Cortrophin Gel franchise to drive growth in 2024 and beyond
© 2024 ANI Pharmaceuticals, Inc. 5 2023 Rare Disease Revenues $112M Est. 2024 $170-$180M +52-61% YoY growth Enter new therapeutic areas Support the patient journey Expand scope and scale of Rare Disease platform • Recently launched a targeted ophthalmology sales force and added a second geographical
Slide 6: Rare Disease: Strong finish to 2023 with continued momentum in 2024
© 2024 ANI Pharmaceuticals, Inc. 6 • Launched 1-mL vial size of Cortrophin Gel during Q4’23, the only approved ACTH therapy indicated for the treatment of acute gouty arthritis flares • Given strong traction in pulmonology, added a second geographical region to pulmonology sales force in Q1 2024 • H
Slide 7: Focused efforts ongoing to increase scope and scale of Rare Disease business
© 2024 ANI Pharmaceuticals, Inc. 7 Focused efforts ongoing to increase scope and scale of Rare Disease business through M&A and in-licensing Assets’ patent protection profile Assets’ peak year revenue forecast Priority 1: Rare disease opportunities in priority therapeutic areas of nephrology, neurol
Slide 8: Capital One 1st Annual Biotech/Biopharma Disruptors Event
© 2024 ANI Pharmaceuticals, Inc. 8 Capital One 1st Annual Biotech/Biopharma Disruptors Event May 14, 2024
ANI Pharmaceuticals — Capital One 1st Annual Biotech/Biopharma Disruptors Event (May 2024) on 6ix